Current State of Investigation in Biomarkers for Breast Cancer

The field of biomarker research for breast cancer is currently experiencing a high level of activity, as new technologies and markers continue to emerge. One particular area of focus is PET imaging for HER2 positive breast cancers.

Challenges in Imaging Heterogeneity

The goal is to develop imaging techniques that can provide real-time information about tumor heterogeneity, similar to how we observe variations in a person’s face. Currently, there are two main markers being used for this purpose: zirconium-89 and trastuzumab (zirconium-89 Zr-Dota-Tate) for HER2 positive breast cancers, as well as gallium-68 and NOTA (gallium-68 Ga-NOTA) in ongoing trials.

Future Developments and Clarifying New Markers

In the next one to two years, we are expected to gain a clearer understanding of these new markers as more trial results become available. Two specific markers to watch for are zirconium-89 Zr-Dota-Tate and gallium-68 Ga-NOTA, but there are many other ongoing trials investigating various biomarkers.

Stay tuned for further developments in the world of breast cancer research as we strive to improve early detection and personalized treatments using advanced imaging technologies and biomarkers.